Therapeutic Monoclonal Antibodies Working Group

Therapeutic Monoclonal Antibodies Working Group

While effective anti-SARS-CoV-2 viral drugs are still unavailable, anti-SARS-CoV2 neutralizing monoclonal antibodies candidates (generally anti-RBD or anti-Spike) represent great hopes for a prompt development of COVID-19 therapeutics.

OUR ROLE

The mAB-Ther Working Group mission is to evaluate the therapeutic potential and prioritize monoclonal antibody candidates in order to clinically test them within one of the clinical platforms already set up by REACTIng (Discovery, Coverage, Covidaxis) under academical promotion.

Composition

The working group is coordinated by Brigitte Autran, Clinical Immunologist – APHP – Pitié Salpetrière /Inserm, and its members are :

Florence Ader, Infectologist- Hôpital de la Croix-Rousse, CIRI
Alexandre Duvignaud, Physician CHU de Bordeaux – Université de Bordeaux – Inserm, Bordeaux
Jérémie Guedj, Methodologist- INSERM, Université Paris Diderot, Hôpital Bichat
Bruno Hoen, Infectologist, Institut Pasteur
Marie Paule Kieny, Immunologist – Inserm
Bernard Fanget, Vaccine R&D – Independent Consultant
Xavier de Lamballerie, Virologist – Aix-Marseille Université
Nathan Peiffer-Smadja, Infectologist – APHP Bichat
Michel de Wilde, Vaccine R&D – Independent consultant
Laurence Weiss, Clinical Immunologist, Hôtel Dieu